Harmine alone tripled beta cell mass, and combined with a GLP-1 agonist like Ozempic, increased it by 700%. The team ...

Evidence is mounting that new therapies already used to treat gut diseases, type 2 diabetes, and obesity may help people with alcohol use disorder (AUD).

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

New research shows how weight loss meds like Wegovy are reshaping alcohol habits, offering new insights into addiction ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potential game-changer. Initially ...

Recent studies show medications like Ozempic, originally designed for type 2 diabetes and weight loss, may help people ...

Lawmakers are considering some small health policy provisions in an end-of-year package – but experts don’t expect anything major.